CANBERRA, March 21 (Xinhua) -- The Australian inventors of the Penthrox inhaler, a unique acute painkiller known as the "green whistle," has opened a new facility in Melbourne as they prepare for rapid global expansion.
Used in hospitals and by paramedics to administer a highly-potent but non-addictive anesthetic called methoxyflurane to patients requiring fast-acting painkillers, the "green whistle" has been used in Australia for decades but has been on the global market for just two years.
Since 2010, the whistle's manufacturer, Medical Developments International (MDI), has seen its market value rocket from around 7 million U.S. dollars to around 225 million dollars, as it is the only company which manufactures the unique product.
In a statement released on Tuesday, CEO of MDI John Sharman said the new warehouse would facilitate rapid expansion to keep up with soaring global demand for the product.
"Penthrox has now been approved for sale in the United Kingdom, Republic of Ireland, France and Belgium," Sharman said.
"We're expecting to enter another 37 markets over the next two years, including Germany, Spain and Italy, and commence the product approval process in the United States."
He said the new warehouse would allow for even faster production and would also create 26 new jobs.
"This state of the art facility allows us to keep up with not only current demand but future growth over the next decade," Sharman said.
"We expect our work force to grow considerably over the next 12 months."